AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars
Executive Summary
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
You may also be interested in...
AAM’s Leonard On Strategizing For Gene Therapies
As ‘hyper personalized’ medicines take hold, generic players need to examine the role they can play in democratizing access to gene therapies alongside complex generics and biosimilars, says AAM president and CEO Dan Leonard.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.